1. Safety and Current Status of the COVID-19 Vaccine among Patients with Breast cancer: A Cross-Sectional Study from China
- Author
-
Shaohua Zhang, Jianbin Li, Ruonan Xu, Qianjun Chen, Gang Sun, Ying Lin, Feng Jin, Xinlan Liu, Zhimin Fan, Yiding Chen, Yali Cao, Xinzheng Li, Jianyun Nie, Guiying Xu, Xiaojia Wang, Yuee Teng, Tao Sun, Hong Liu, Jing Luo, Cuizhi Geng, Man Li, Ting Luo, Yinhua Liu, Fu-Sheng Wang, Zefei Jiang, and Wang Haijuan
- Subjects
Medicine - Abstract
Abstract. In this study, we aimed to explore the safety and vaccination coverage data of Chinese patients with breast cancer receiving coronavirus disease 2019 (COVID-19) vaccination. The patients were recruited from 41 hospitals across 20 Chinese provinces. The vaccination coverage was approximately 22.4%, and the frequency of total adverse events was 13.3% after the first dose and 9.9% after the second dose. The most frequent adverse reaction within 14 days of the first dose was local pain (5.7%). Unvaccinated patients were very likely to reject the vaccine rather than be hesitant in patients with old age (odds ratio [OR], 1.238; 95% confidence interval [CI], 1.101–1.391), chronic disease history (OR, 1.189; 95% CI, 1.057–1.337), and cancer relapse (OR, 1.398; 95% CI, 1.233–1.585). Of the unvaccinated patients with breast cancer, 54.1% opted to receive COVID-19 vaccines if more data were available. Considering the safety but low vaccination coverage for breast cancer, increased positive attitudes and acceptance toward COVID-19 vaccines are important.
- Published
- 2023
- Full Text
- View/download PDF